Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Status:
Completed
Trial end date:
2021-03-09
Target enrollment:
Participant gender:
Summary
Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination
with ipilimumab. Phase 2 is a randomized study that will evaluate the safety and efficacy of
talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.